Liraglutide for Childhood Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects.Participants will either get liraglutide or placebo. Which treatment the participants get is decided by chance. Liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. The participant will get 1 injection every day.In addition to taking the medicine, the participants will have talks with the study staff about healthy food choices, how they can be more physically active and what can be done to help the participants to lose weight.The study will last for about 96 weeks (almost 2 years). The participants will have 18 clinic visits and 10 phone or video calls with the study doctor/staff. Participant will have blood samples taken, have 1 test to check the heart, 1 hand X-ray taken and must fill in a diary between some of the visits.
Do I need to stop my current medications to join the trial?
The trial requires that participants have not taken any medication for obesity in the past 90 days before screening. If you are currently on such medication, you would need to stop it to be eligible.
Is liraglutide safe for use in humans?
How is the drug liraglutide unique for treating childhood obesity?
Liraglutide is unique because it is a once-daily injection that helps control appetite by acting on the brain, and it was originally used for type 2 diabetes and adult obesity. It is now being explored for childhood obesity, offering a novel approach compared to traditional lifestyle changes alone.34567
What data supports the effectiveness of the drug liraglutide for childhood obesity?
Research shows that liraglutide, used under the brand name Saxenda, has been effective in reducing body mass index (BMI) in adolescents with obesity. It works by helping control appetite and has been approved for weight management in adults, suggesting potential benefits for younger populations as well.13489
Who Is on the Research Team?
Clinical Transparency (dept. 2834)
Principal Investigator
Novo Nordisk A/S
Are You a Good Fit for This Trial?
This trial is for children aged 6 to below 12 with obesity, who haven't had significant weight changes in the last 3 months and have not been on obesity medication recently. They should be struggling to lose weight through lifestyle changes alone. Children with type 2 diabetes can join if their HbA1c levels are low enough.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either liraglutide or placebo for weight management, with daily injections and lifestyle counseling
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of BMI and adverse events
Long-term follow-up
Participants continue to be monitored for long-term safety and health outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Liraglutide
- Placebo
Liraglutide is already approved in United States, European Union for the following indications:
- Type 2 diabetes mellitus treatment
- Cardiovascular risk reduction in adults with type 2 diabetes and heart disease
- Weight loss treatment in adults and children aged 12 and older with obesity
- Type 2 diabetes mellitus treatment
- Cardiovascular risk reduction in adults with type 2 diabetes and heart disease
- Weight loss treatment in adults and children aged 12 and older with obesity
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novo Nordisk A/S
Lead Sponsor
Lars Fruergaard Jørgensen
Novo Nordisk A/S
Chief Executive Officer since 2017
MSc in Finance and Business Administration, Aarhus School of Business, Aarhus University, Denmark
Martin Holst Lange
Novo Nordisk A/S
Chief Medical Officer since 2021
MD from University of Copenhagen